Some scientists are concerned about the rates of vision loss among patients who take Zepbound and other GLP-1s
A 2025 human randomized-controlled trial by Zhang Y., et al
If Aetna denies Zepbound coverage, patients can explore options like medical exceptions, manufacturer savings cards, discount programs, or switching to covered alternatives such as Mounjaro or Contrave to reduce out-of-pocket costs
The first to be approved was Byetta
Bioactive Plant Compounds Green Tea Extract (EGCG) Epigallocatechin gallate (EGCG), the primary catechin in green tea, has shown promise for enhancing GLP-1 activity
Sugary drinks and ultra-processed foods These work against the blood sugar benefits that GLP-1 medications are partly designed to provide